A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer

NCT00701558 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer Metastatic

Interventions

DRUG: Erlotinib
DRUG: Gemcitabine

Sponsor

Hoffmann-La Roche